BMB Reports : Therapeutic effect of a TM4SF5-specific peptide vaccine against colon cancer in a mouse model = BMB Reports : Therapeutic effect of a TM4SF5-specific peptide vaccine against colon cancer in a mouse model

다국어 초록 (Multilingual Abstract)

Molecular-targeted therapy has gained attention because of its high efficacy and weak side effects. Previously, we confirmed that transmembrane 4 superfamily member 5 protein (TM4SF5) can serve as a molecular target to prevent or treat hepatocellular carcinoma (HCC). We recently extended the application of the peptide vaccine, composed of CpG-DNA, liposome complex, and TM4SF5 peptide, to prevent colon cancer in a mouse model. Here, we first implanted mice with mouse colon cancer cells and then checked therapeutic effects of the vaccine against tumor growth. Immunization with the peptide vaccine resulted in robust production of TM4SF5-specific antibodies, alleviated tumor growth, and reduced survival rate of the tumor-bearing mice. We also found that serum levels of VEGF were markedly reduced in the mice immunized with the peptide vaccine. Therefore, we suggest that the TM4SF5-specific peptide vaccine has a therapeutic effect against colon cancer in a mouse model. [BMB Reports 2014; 47(4): 215-220]

참고문헌 (Reference)

1 Klinman, D. M., "Use of CpG oligodeoxynucleotides as immune adjuvants" Immunol. Rev 199 : 201 ~ 216 -, 2004

2 Schreiber, T. H., "Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art. Semin" Immunol 22 : 105 ~ 112, 2010

3 Yoshiji, H., "The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor" Clin. Cancer Res 7 : 1073 ~ 1078 -, 2001

4 Lee, S. A., "Tetraspanin TM4SF5 mediates loss of contact inhibition through epithelial- mesenchymal transition in human hepatocarcinoma" J. Clin. Invest 118 : 1354 ~ 1366 -, 2008

5 Yoshiji, H., "Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis" Cancer Res 59 : 4413 ~ 4418 -, 1999

6 Kwon, S., "Prophylactic effect of a peptide vaccine targeting TM4SF5 against colon cancer in a mouse model" Biochem. Biophys. Res. Commun 435 : 134 ~ 139 -, 2013

7 Lee, Y, "Production of epitope-specific antibodies using peptide-CpG-ODN-liposome complex without carriers and their application as a cancer vaccine in mice" Oncoimmunology 1 : 1215 ~ 1217 -, 2012

8 Kim, D., "Production of antibodies with peptide- CpG-DNA-liposome complex without carriers" BMC Immunol 12 : 29 ~ -, 2011

9 Kwon, S., "Prevention and therapy of hepatocellular carcinoma by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex without carriers" PLoS One 7 : e33121 ~ -, 2012

10 Caihong Zhou, "Overexpression of TTRAP inhibits cell growth and induces apoptosis in osteosarcoma cells" BMB Reports 46 (2) : 113 ~ 118 -, 2013

11 Carson, D. A., "Oligonucleotide adjuvants for T helper 1 (Th1)-specific vaccination" J. Exp. Med 186 : 1621 ~ 1622 -, 1997

12 Mercurio, A. M., "Non-angiogenic functions of VEGF in breast cancer" J. Mammary Gland Biol. Neoplasia 10 : 283 ~ 290 -, 2005

13 Tanaka, S., "Molecular targeted therapy for hepatocellular carcinoma in the current and potential next strategies" J. Gastroenterol 46 : 289 ~ 296 -, 2011

14 Llovet, J. M., "Molecular targeted therapies in hepatocellular carcinoma" Hepatology 48 : 1312 ~ 1327 -, 2008

15 Kwon, S., "Induction of immunological memory response by vaccination with TM4SF5 epitope-CpG-DNA-liposome complex in a mouse hepatocellular carcinoma model" Oncol. Rep 29 : 735 ~ 740 -, 2013

16 Lee, K. W., "Immunostimulatory oligodeoxynucleotide isolated from genome wide screening of Mycobacterium bovis chromosomal DNA" Mol. Immunol 43 : 2107 ~ 2118 -, 2006

17 Muller-Pillasch, F., "Identification of a new tumour-associated antigen TM4SF5 and its expression in human cancer" Gene 208 : 25 ~ 30 -, 1998

18 Choi, K. S., "Hypoxia-induced angiogenesis during carcinogenesis" J. Biochem. Mol. Biol 36 : 120 ~ 127 -, 2003

19 Montomoli, E., "Current adjuvants and new perspectives in vaccine formulation" Expert. Rev. Vaccines 10 : 1053 ~ 1061 -, 2011

20 Chu, R. S., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity" J. Exp. Med 186 : 1623 ~ 1631 -, 1997

21 Krieg, A. M., "CpG motifs in bacterial DNA and their immune effects" Annu. Rev. Immunol 20 : 709 ~ 760 -, 2002

22 Davis, H. L., "CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen" J. Immunol 160 : 870 ~ 876 -, 1998

23 Bode, C., "CpG DNA as a vaccine adjuvant" Expert. Rev. Vaccines 10 : 499 ~ 511 -, 2011

24 Choi, S., "Cooperation between integrin alpha5 and tetraspan TM4SF5 regulates VEGF-mediated angiogenic activity" Blood 113 : 1845 ~ 1855 -, 2009

25 Abbas, A., "Cellular and molecular immunology, 6th ed" Saunders, Elsevier : 351 ~ 373, 2010

26 Aly, H. A., "Cancer therapy and vaccination" J. Immunol. Methods 382 : 1 ~ 23 -, 2012

27 Lee, S. A., "Blockade of four-transmembrane L6 family member 5 (TM4SF5)-mediated tumorigenicity in hepatocytes by a synthetic chalcone derivative" Hepatology 49 : 1316 ~ 1325 -, 2009

28 김남훈, "Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells" BMB Reports 46 (1) : 59 ~ 64, 2013

29 김동범, "Adjuvant effect of liposome-encapsulated natural phosphodiester CpG-DNA" BMB Reports 44 (11) : 758 ~ 763, 2011

30 김동범, "Activation of Toll-like receptor 9 and production of epitope specific antibody by liposome-encapsulated CpG-DNA" BMB Reports 44 (9) : 607 ~ 612, 2011